NIH-funded research NIH-funded research

Adapting and testing a behavioral program to prevent FASD and adverse infant outcomes

Official title: Adapting and testing a behavioral intervention to prevent FASD and adverse infant outcomes

Funded at Philadelphia College of Osteopathic Med · NIH-11595604 · Data updated 2026-11-12

A behavioral program is being tailored and tested to help pregnant and breastfeeding women reduce alcohol and other substance use to protect babies in South Africa.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionPhiladelphia College of Osteopathic Med
NIH-funded
Lab location1 site (Philadelphia, United States)
Project startApril 13, 2026
Project endAugust 31, 2028
Funding year2026
Award (this year)$221,790
NIH project number3R33AA030043-04S1
Project IDNIH-11595604 on NIH RePORTER

Who could benefit from this research

Could help

Pregnant or lactating individuals who report alcohol use (and co-use of tobacco or cannabis) in South Africa and are willing to participate in a behavioral intervention.

Less likely to help

Individuals who do not use alcohol or other substances during pregnancy/lactation or who cannot participate in behavioral interventions may not receive direct benefit.

What this research studies

This project aims to adapt an evidence-based behavioral intervention to reduce polysubstance use during pregnancy and lactation, with the goal of lowering fetal alcohol spectrum disorder and other adverse birth outcomes. The study will tailor strategies like contingency management to the South African context and test their feasibility and impact among pregnant and lactating individuals. It will address co-occurring use of alcohol, tobacco, and cannabis, which together worsen birth outcomes. By engaging women in a supportive program, the research seeks to promote healthier behaviors for both mother and child. The work is conducted in collaboration with the Philadelphia College of Osteopathic Medicine, under a pilot-scale R33 grant in SA and the U.S. research setting.

Why it matters

Potential benefit: If successful, the program could reduce prenatal substance use and the incidence of FASD, improving cognitive and physical development outcomes for children.

How similar studies have gone: Contingency management approaches have shown success in reducing prenatal substance use in other settings, though this specific adaptation in SA is novel.

Where this research is happening

  • Philadelphia College of Osteopathic Med
    Philadelphia, United States
    Active

Researchers

  • Principal investigator: Washio, Yukiko — Philadelphia College of Osteopathic Med
  • Study coordinator: Washio, Yukiko

Related research

Other NIH-funded projects on the same topics.

  • Adapting a Behavioral Program to Prevent FASD and Harmful Infant Outcomes in SA

    A program is being adapted and tested to help pregnant and breastfeeding women in South Africa reduce alcohol, tobacco, and cannabis use to prevent fetal alcohol spectrum disorder and other infant problems.

    NIH research Philadelphia College of Osteopathic Med · Philadelphia, United States · NIH-11525904

  • CD38 and muscle energy in spinal and bulbar muscular atrophy

    The team is trying to lower CD38 to boost muscle energy and help men with spinal and bulbar muscular atrophy (SBMA).

    NIH research Philadelphia College of Osteopathic Med · Philadelphia, United States · NIH-11251998

  • Investigating CD38 as a potential treatment target for spinal and bulbar muscular atrophy

    This study is looking at a condition called spinal and bulbar muscular atrophy (SBMA) that mainly affects men, and it aims to find out how a specific enzyme called CD38 might help improve energy in muscle cells, which could lead to new treatments for people with this condition.

    NIH research Philadelphia College of Osteopathic Med · Philadelphia, United States · NIH-11020175

  • Creating a zebrafish model to study a genetic neuromuscular disease.

    This study is creating a special zebrafish model to help find new treatments for spinal and bulbar muscular atrophy (SBMA), a genetic disease that mainly affects men, so researchers can quickly test potential therapies in a way that's both fast and affordable.

    NIH research Philadelphia College of Osteopathic Med · Philadelphia, United States · NIH-10784254

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.